Skip to main content

Table 3 Overview of selected studies

From: Efficacy of commercially available biological agents for the topical treatment of cervical intraepithelial neoplasia: a systematic review

  Author Treatment regimen Placebo Delivery system (by investigator/patient) Disease Number treated/placebo Regression treated (%)/placebo (%) Remission treated (%)/placebo (%) FU, after end of treatment
1 Sidhu 1997 [14] 20 mg of 5-FU for 24 h (one application) Cytotoxic drug delivery system without 5FU Bilaminar bioadhesive polymeric film CIN1–2 48/46 67%/72% (p = 0.76)   6 months
2 Rahangdale 2014 [13] 2 g of 5% 5-FU once every 2 weeks for a total of 16 weeks (eight applications) Observation, no placebo Vaginal applicator (+ tampon) (by patient) CIN2 28/27 93%/56% (p = 0.01) 86%/44% 10 weeks
3 Meyskens 1994 [28] 1.0 ml of 0.375% atRA or a placebo cream for 24 h. Start: daily for 4 days; months 3 and 6: daily for 2 days (eight applications) Polyethylene glycol 400, butylated hydroxytoluene, 55% alcohol Cervical cap + collagen sponge (by investigator) CIN2 CIN3 75/66 40/51   43%/27% (p = 0.41) 25%/31% (p = 0.33) 21 months
4 Ruffin 2004 [29] 0.16–0.28% - 0.36% atRA or placebo daily for four consecutive days (four applications) Same carrier base to compound atRA cervical cap + collagen sponge (by investigator) CIN2 CIN3 29–32–34/24 16–12–13/14 83–87–74%/70%
57–58–35%/57%
62–50–50% /62%
44–50–14/21%
11 weeks
5 Van Pachterbeke 2009 [16] 3 ml cidofovir 2% in Intrasite gel (for 4 h) or placebo, three applications in 1 week Sterile water + Intrasite gel Cervical cap (by investigator) CIN2–3 23/25   61%/20% (p = 0.01) 6 weeks
6 Grimm 2012 [30] 6.25 mg imiquimod (overnight) 2 g Adeps solidus Vaginal suppositories (by patient) CIN2–3 28/27 79%/41% (p = 0.009) 50%/15% (p = 0.08) 4 weeks
week 1–2: 1 suppo/w
week 3–4: 2 suppo/w
week 5–16: 3 suppo/w
(max. 42 applications)
  1. CIN cervical intraepithelial neoplasia, FU follow-up, mIU million international units